Antiangiogenic Therapy for High-Grade, Recurrent Brain Tumors
Name of the Trial
Why Is This Trial Important?
A chemotherapy drug known as LY317615 may stop the growth of gliomas by halting blood flow to the tumor, a process called antiangiogenesis. This trial seeks to establish the tumor-fighting ability of LY317615 in patients with high-grade, recurrent gliomas and assess the side effects the drug may have on patients.
"Recurrent malignant glioma is a desperate disease for which there are very few adequate treatments," said Dr. Fine. "This drug could be a highly potent therapy, though, because preclinical studies show that it may have both an indirect antiangiogenic effect as well as a direct cancer-killing effect on gliomas. Early results have already demonstrated the ability of LY317615 to stop the growth and shrink the tumor in some patients.
"Additionally, the trials of LY317615 to date have shown that the agent has minimal side effects," he said.
Who Can Join This Trial?
Where Is This Trial Taking Place?
Who to Contact
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.